Wettig Thane's Form 4 filing
Kyntra Bio, Inc.KYNB · filed Mar 25, 2025
- Accession no.
- 0001415889-25-008872
- Filed
- Mar 25, 2025, 9:00 AM ET
- Trade date
- Mar 24, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $50.7K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wettig ThaneCIK 0001815638 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 24, 2025 | Common Stock | PPurchaseAcquired | +145,000 | $0.3494F1 | +$50,663 | 543,329 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.34 to $0.37. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.